Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50 (101.22% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Show:
DateFirmActionRatingPrice TargetDetailsShare
6/13/2014Roth CapitalInitiated CoverageBuy$19.00ViewTweet This Rating  Share This Rating on StockTwits
3/28/2014Stifel NicolausLower Price Target$16.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
3/7/2014Roth CapitalInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
11/15/2013Stifel NicolausReiterated RatingBuy$16.00 -> $13.00ViewTweet This Rating  Share This Rating on StockTwits
8/19/2013SunTrustInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
8/19/2013JMP SecuritiesInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
8/19/2013Stifel NicolausInitiated CoverageBuy$16.00ViewTweet This Rating  Share This Rating on StockTwits
8/19/2013Piper JaffrayInitiated CoverageOverweightViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2012 forward)